# Portrai

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/portrai

- Industry: Pharmaceuticals
- Headquarters: Seoul, South Korea
- Website: www.portrai.io/
- Total disclosed funding: $14M
- Latest round: Series B (Dec 2, 2025)
- Investors on record: 10

## About

Based in South Korea, Portrai Inc. specializes in advanced spatial transcriptomics, offering innovative solutions to biopharma for target discovery and therapeutic development, enhancing precision medicine strategies.Portrai Inc. was founded in 2021 in Seoul, South Korea, focusing on spatial transcriptomics. The company has completed three deals to date, with its most recent funding round being a Series B where it raised KRW 14.5 billion on December 2, 2025, from investors including STIC Ventures and BNH Investment. The founder’s background is not widely documented, and there are no known subsidiaries or parent companies.Portrai specializes in advanced spatial transcriptomics to provide innovative solutions for target discovery and therapeutic development in biopharma. The company's core offerings include a comprehensive spatial database that houses over 2,000 patient samples and more than 50 million spatially resolved cells from various solid tumors. This database enables clients to rapidly identify therapeutic targets and evaluate potential disease indications with high spatial precision. Portrai collaborates with biopharma innovators globally, providing expertise in spatial biology to co-develop next-generation therapies aimed at enhancing precision medicine strategies. The company's services cater to healthcare professionals and researchers across North America, Europe, and Asia, focusing on driving advancements in drug development and personalized treatment approaches.Portrai's revenue generation model is primarily built on partnerships and collaborations with biopharma companies and research institutions. The company engages in strategic partnerships that may involve co-development agreements for therapeutic targets and the use of their extensive spatial database. Transactions typically occur through B2B arrangements, where clients access Portrai's database and services to enhance their drug development processes. Specific pricing structures for these services are tailored to the needs of individual clients and may vary based on the scope of collaboration and access to the spatial transcriptomics platform. Portrai aims to provide value through its offerings, particularly in the development of spatial biomarkers and companion diagnostics that support advanced therapeutic efficacy.In December 2025, Portrai Inc. raised KRW 14.5 billion in Series B funding to accelerate database commercialization, multi-omics drug development, and global collaborations with pharmaceutical companies. The company plans to launch new products to enhance its spatial transcriptomics offerings and expand its market presence in North America and Europe by the end of 2026.

## Funding rounds

- Series B, Dec 2, 2025, $9.9M — CKD Venture Capital, BonAngels Venture Partners, Kakao Ventures, BNH Investment, STIC Ventures, Pearl Abyss Capital, Envisioning Partners
- Series A, Mar 1, 2023, $3.9M — DSC Investment, Kakao Ventures, Schmidt
- Angel, Aug 31, 2021, $0.7M — Saehan Venture Capital

## Investors

- Saehan Venture Capital (https://capitalatlas.ai/funds/saehan-venture-capital) — Angel
- DSC Investment (https://capitalatlas.ai/funds/dsc-investment) — Series A
- Kakao Ventures (https://capitalatlas.ai/funds/kakao-ventures) — Series A, Series B
- Schmidt (https://capitalatlas.ai/funds/schmidt) — Series A
- CKD Venture Capital (https://capitalatlas.ai/funds/ckd-venture-capital) — Series B
- BonAngels Venture Partners (https://capitalatlas.ai/funds/bonangels-venture-partners) — Series B
- BNH Investment (https://capitalatlas.ai/funds/bnh-investment) — Series B
- STIC Ventures (https://capitalatlas.ai/funds/stic-ventures) — Series B
- Pearl Abyss Capital (https://capitalatlas.ai/funds/pearl-abyss-capital) — Series B
- Envisioning Partners (https://capitalatlas.ai/funds/envisioning-partners) — Series B